**ORIGINAL RESEARCH ARTICLE**

# The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

Michele Fusaroli[1] · Francesco Salvo[2,3] · Bernard Begaud[2] · Thamir M. AlShammari[4] · Andrew Bate[5,6] · Vera Battini[7] · Andreas Brueckner[8] · Gianmario Candore[9] · Carla Carnovale[7] · Salvatore Crisafulli[10] · Paola Maria Cutroneo[11] · Charles Dolladille[12,13] · Milou-Daniel Drici[14] · Jean-Luc Faillie[15] · Adam Goldman[16,17] · Manfred Hauben[18,19] · Maria Teresa Herdeiro[20] · Olivia Mahaux[5] · Katrin Manlik[9] · François Montastruc[21,22] · Yoshihiro Noguchi[23] · G. Niklas Norén[24] · Roberta Noseda[25] · Igho J. Onakpoya[26] · Antoine Pariente[2,3] · Elisabetta Poluzzi[1] · Myriam Salem[27] · Daniele Sartori[24,28] · Nhung T. H. Trinh[29] · Marco Tuccori[30] · Florence van Hunsel[31,32] · Eugène van Puijenbroek[31,32] · Emanuel Raschi[1] · Charles Khouri[33,34]

## Abstract

**Background and aim** Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their methods and results are generally poorly reported in published articles and existing guidelines do not capture the specific features of disproportionality analyses. We here describe the development of a guideline (REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance [READUS-PV]) for reporting the results of disproportionality analyses in articles and abstracts.

**Methods** We established a group of 34 international experts from universities, the pharmaceutical industry, and regulatory agencies, with expertise in pharmacovigilance, disproportionality analyses, and assessment of safety signals. We followed a three-step process to develop the checklist: (1) an open-text survey to generate a first list of items; (2) an online Delphi method to select and rephrase the most important items; (3) a final online consensus meeting.

**Results** Among the panel members, 33 experts responded to round 1 and 30 to round 2 of the Delphi and 25 participated to the consensus meeting. Overall, 60 recommendations for the main body of the manuscript and 13 recommendations for the abstracts were retained by participants after the Delphi method. After merging of some items together and the online consensus meeting, the READUS-PV guidelines comprise a checklist of 32 recommendations, in 14 items, for the reporting of disproportionality analyses in the main body text and four items, comprising 12 recommendations, for abstracts.

**Conclusions** The READUS-PV guidelines will support authors, editors, peer-reviewers, and users of disproportionality analyses using individual case safety report databases. Adopting these guidelines will lead to more transparent, comprehensive, and accurate reporting and interpretation of disproportionality analyses, facilitating the integration with other sources of evidence.

### Key Points

Misreported and misinterpreted disproportionality analyses contribute to poor research quality.

The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV) guidelines will help researchers to adequately report their study and interpret the results.

Adis

# 1 Introduction

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) or any other possible drug-related problems [1]. The main data source for detecting new ADRs after drug marketing approval consists of databases of individual case safety reports (ICSRs) recording suspected ADRs—whether spontaneous or generated within active surveillance activities [2–5]. A range of methods have been developed for mining these databases [6]. Disproportionality analyses are statistical methods that aim at quantifying the association between drug(s) and adverse event(s) comparing the number of observed ICSRs recording both the drug(s) and the event(s) with the number of ICSRs that would be expected in the absence of any association between the drug and the event, based on the underlying drug and event rates within the same ICSR database [7]. These analyses generate a signal of disproportionate reporting (SDR) when the statistic significantly exceeds a predefined threshold [1, 8, 9]. Because of the lack of exposure data and the unquantified under- and selective reporting, SDRs cannot be interpreted in themselves as conclusive scientific evidence of a causal relationship between a drug and an adverse event [1, 10]. Consistently, a signal of suspected causality [11, 12] should only be presented after the SDR has undergone an initial triage including, whenever possible, a case-by-case assessment of the ICSRs and the contextualization within knowledge already accrued from other sources of evidence (e.g., clinical trials, observational studies, case reports/series, literature, and animal experiments) [3, 4, 13, 14].

Nowadays, disproportionality analyses are increasingly used by multiple stakeholders, including pharmaceutical companies, regulatory agencies, and researchers. Their findings are frequently published in both specialized pharmacology journals and general medical journals [15–18]. However, they are often poorly reported and interpreted [17, 19]. Indeed, over 75% of published disproportionality studies failed to report essential elements needed to understand and reproduce the analyses and results, and more than two thirds of authors over- or misinterpreted their findings, notably in the abstract [17, 19]. Poor reporting and interpretation hamper the use and ability to assess research findings and contribute to research waste (i.e., avoidable inappropriate conduct and dissemination of research) [20–22]. Reporting guidelines, representing a minimum standard of items that should be reported in published articles, have therefore been developed for a range of study designs [23–26]. However, the design of disproportionality analyses has specific features that are not covered by existing reporting guidelines for observational and pharmacoepidemiological studies such as Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely collected health Data statement for PharmacoEpidemiology (RECORD-PE) [25, 26]. We have therefore developed a guideline specifically tailored to the reporting and interpretation of disproportionality analyses: the REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV).

The READUS-PV guidelines are intended as a guidance to support the reporting (and the publication) of disproportionality analyses to ensure that readers can easily determine what was planned (i.e., the research question), done (i.e., the methodology used), and found (i.e., the results and drawn conclusions). They should therefore not be considered as a tool to explicitly assess the quality of a published manuscript or the validity of an SDR as a true safety signal, which also requires considering additional methodological aspects. Nonetheless, these guidelines can indirectly improve the quality of research by pointing to items that should be already addressed during study design and reducing the risk of misinterpretation of results. In this regard, these guidelines should be viewed in conjunction with other recommendations on signal detection practices, such as those promoted by pharmacovigilance experts, the Innovative Medicine Initiative Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (IMI PROTECT) for methodological considerations on disproportionality analyses, and by regulatory agencies for assessment of safety signals [12, 27–29]. The READUS-PV statement comprises a checklist of 14 items recommended for reporting disproportionality analyses, and four additional items for the abstract. Box 1 includes a glossary of terms used throughout the READUS-PV statement. This article is simultaneously published with an "explanation and elaboration" article providing additional reporting guidance for each item, along with examples of good reporting [30].

**Box 1** Glossary of terms

| Term | Definition |
| --- | --- |
| Adverse event* | Any untoward (i.e., noxious and unintended) medical occurrence that develops in an individual exposed to a medicinal product. Possible conditions of exposure include appropriate medical use, medication errors, off-label use, overdose, misuse, abuse, and occupational exposure. The medical occurrence does not necessarily have a causal relationship with the exposure. |
| Adverse drug reaction (ADR)* | Any adverse event characterized by an at least reasonable possibility that the medicinal product has caused the event. |
| Causality assessment* | The process of evaluating and assigning a causal judgment to an observed association between a medicinal product and an adverse event, at the level of either individual ICSRs or case series. Causality assessment can rely on expert judgment/global introspection, structured guidelines and algorithms, or probabilistic approaches [31]. |
| Drug | A drug is usually defined as any chemical substance that causes a change in an organism's physiology or psychology when consumed. To be consistent with pharmacovigilance terminology (e.g., drug-related problem, adverse drug reaction, drug–event combination) we adopted the use of the term drug, but these guidelines are valid for disproportionality analyses on any medicinal product used in the prevention, diagnosis, or cure of diseases (e.g., vaccine, medical device, gene therapy, cell therapy, supplements). |
| Drug–event combination | The specific combination of medicinal product(s) and event(s) of interest. |
| Individual case safety reports (ICSRs)** | Format and content for the reporting of one or several adverse events occurred in a single individual at a specific point of time. It accommodates clinical phenotypes involving multiple events that may manifest sequentially over time. |

| Term | Definition |
| --- | --- |
| Pharmacovigilance* | The science and activities relating to the detection, assessment, understanding, and prevention of ADRs or any other drug-related problem. |
| Case-by-case analysis | Analysis of each ICSR recording the drug–event combination to collect further information useful for the causality assessment. |
| Safety signal* | Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association or a new aspect of a known association between medicinal product(s) and adverse event(s). The information is judged to be sufficient to justify verificatory actions. |
| ICSR database | A surveillance database that relies on ICSRs submitted by multiple stakeholders (healthcare providers, consumers, and pharmaceutical companies) because of spontaneous initiative or mandatory reasons). |
| Signal of disproportionate reporting (SDR)* | A statistical association between medicinal product(s) and event(s) identified by any disproportionality analysis within an ICSR database. |

* Definitions adapted from the Council for International Organizations of Medical Sciences (CIOMS) cumulative glossary with a focus on pharmacovigilance (version 2.1)

**Definition adapted from the European Medicines Agency (EMA) definition of ICSR

## 2 The READUS-PV Checklist

### 2.1 Conception and Development of the Checklist

We followed the recommendations by the Enhancing the QUality And Transparency Of health Research (EQUATOR) Network for the development of reporting guidelines [32]. The protocol was registered with the EQUATOR Network website on March 7, 2022, and published on a dedicated website (https://readus-statement.org/).

Based on a bibliometric analysis and taking into account expertise and geographical provenance, we established a diverse group of international individuals from universities, the pharmaceutical industry, and regulatory agencies, with

expertise in pharmacovigilance, disproportionality analyses, and assessment of safety signals. Of the 70 invitations sent out, 34 experts agreed to take part in the project. We followed a three-step process to develop the checklist: (1) an open-text survey to generate a first list of items to be potentially included in the checklist, (2) a modified Delphi method to select and rephrase items important for the reporting, and (3) a final online consensus meeting.

## 2.2 Open-Text Survey

We first used an open-text survey in which the participants were asked to suggest items that they thought should be included in articles reporting disproportionality analysis results. To guide participants in their suggestions, we used the same subsection of the STROBE and RECORD-PE checklists (e.g., background/objective/study design/data source). Among the panel members, 32 participants compiled the open-text survey. The steering committee (MF, FS, ER, CK) then summarized the comments retaining all unique ideas (regardless of frequency) and proposed an initial list of 97 items.

### 2.2.1 The Delphi Method

Panel members were asked to decide whether they believed the proposed items should be included in the READUS-PV reporting guideline, using an online modified Delphi method through Sphinx Online© software version 4.30. We used a logical algorithm to select items to be included in the following steps (Supplementary Figure 1, see the electronic supplementary material). Briefly, items were included in the checklist if more than 80% of participants agreed, with no major comments on wording or concept. In the case of major comments, independently of the agreement rate, items were modified and proposed to the second round, in which the agreement on both the phrasing and the inclusion of the item in the checklist were assessed. Among the panel members, 33 experts responded to round 1 and 30 to round 2 of the Delphi. Overall, 60 recommendations for the main body of the manuscript and 13 recommendations for the abstracts were retained by participants after the Delphi method.

### 2.2.2 Online Consensus Meeting

Before the meeting, the steering committee merged related items, harmonized terminologies, and shared with all participants the draft version of the checklist. All participants were also asked to review the final list of items and share comments to be discussed in the final meeting through a shared online document. There were 25 attendees from 14 countries participating in the online consensus meeting (https://readus-statement.org/). Each item selected in previous rounds

of the Delphi method was discussed, and participants were invited to share their views on the proposal and vote for final decisions about wording of items. In this step, minor comments collected in previous rounds were considered. Decisions were adopted by vote, and items were rediscussed and rephrased, if necessary, until at least 80% of participants agreed. The panel agreed on 14 items for manuscript body, and four items for the abstract.

### 2.2.3 Post-Meeting Activities

Following the online consensus meeting, the steering committee of READUS-PV prepared the first draft of the two manuscripts: the statement and the explanation and elaboration. The manuscripts were shared with the entire panel for two rounds of revisions.

## 2.3 Using the READUS-PV Checklist

The READUS-PV checklist templates for the manuscript body (Table 1) and the abstract (Table 2) can be downloaded from either the electronic supplementary material (Supplementary Tables 1 and 2) or the READUS-PV statement website (http://www.readus-statement.org/). We recommend authors refer to READUS-PV already when designing the study to achieve a more complete and transparent documentation. Journals and publishers may impose restriction on word count, manuscript structure, and number of tables and figures allowed. The recommendation for placing information in specific manuscript sections should not be viewed as mandatory, but relevant information should still be presented, if not in the manuscript body, at least in properly referenced supplementary materials, protocols, and/or data repositories (e.g., Open Science Framework, Dryad, Figshare).

## 3 Discussion

The READUS-PV guidelines were designed to improve the reporting of disproportionality analyses using ICSR databases. The completeness and accuracy of research reporting are ethical requirements endorsed by leading international statements and recommendations [33, 34]. Indeed, complete reporting enables readers to assess the appropriateness of methods, and thus the validity of research results. Moreover, improving the transparency of the reporting, these guidelines bear the potential to enhance the reproducibility and replicability of disproportionality analysis.

Reporting guidelines have been shown to improve the completeness and quality of reporting (cf. Consolidated Standards of Reporting Trials [CONSORT] for the reporting of randomized controlled trials) [35, 36]. However,

**Table 1** The READUS-PV checklist

| Section and topic | Item # | Checklist item |
| --- | --- | --- |
| *Title* | | |
| | 1a | If disproportionality analyses are a prominent component of the published study, the study should be identified as a "disproportionality analysis." The type of data and name of the database(s) should be specified. |
| | 1b | Report the name of adverse event(s) and/or drug(s) under study, when applicable. |
| *Introduction* | | |
| Background | 2a | Describe the drug(s) and its utilization, the nature of the adverse event(s) under study and its frequency, and the existing knowledge on the drug–event combination. |
| | 2b | Specify the rationale for performing the analysis, e.g., as part of routine pharmacovigilance, to investigate an overall safety profile, or to assess a pre-specified hypothesis. |
| | 2c | Explain why individual case safety report databases and disproportionality analysis are suitable to fill the knowledge gap. |
| Objectives | 3 | State specific objectives, identifying the adverse event(s), the drug(s), and the reference group, including any pre-specified hypothesis, if applicable. |
| *Methods* | | |
| Study design | 4a | Identify the study (i.e., "disproportionality analysis") and the type of data used (e.g., "individual case safety reports"). |
| | 4b | Provide an outline of the entire study design, including primary and sensitivity analyses performed, and other designs such as case-by-case analysis or literature review. |
| Data description, access, and pre-processing | 5a | Specify the name of the database(s), the database(s) custodian, and the coverage. Specify the type/number of drugs included within the database and the thesaurus, taxonomies, or ontologies used for coding drugs and events. |
| | 5b | Specify the extraction dates and describe and justify all choices used for data pre-processing, including any data transformation or exclusion, if appropriate. |
| Variables definition | 6a | Describe the study population, including any restriction. |
| | 6b | Describe the nature and the meaning of key variables assessed in the work. |
| | 6c | Specify and justify any grouping of drugs or events. For drugs, specify and justify whether active ingredients/trade names/salts were considered and/or the selected role. |
| | 6d | Describe any additional data source used, the type of data, and how they interact with individual case safety reports. |
| Statistical methods | 7a | Present any descriptive analysis performed, specifying variables investigated, statistical tests, and significance thresholds. |
| | 7b | Describe the measure(s) selected for the disproportionality analysis including any threshold used to identify signals of disproportionate reporting. Explain the reason for this choice if applicable. |
| | 7c | Clearly describe any sensitivity analysis and any tool to control confounding, including any restriction, subgroup, stratification, adjustment, or interaction. |
| | 7d | Specify the variables and methods used for the case-by-case analysis, including any algorithm or criteria used to assess causality, if performed. |
| | 7e | Specify any statistical methods used for other data sources. |
| *Results* | | |
| Participants | 8a | Specify the number of individual case safety reports included at each stage, including reasons for exclusion. |
| | 8b | Provide key demographic and clinical characteristics of cases, if possible comparing cases with any appropriate reference group. |
| Disproportionality analysis | 9 | Present all results including confidence intervals. Present also results of sensitivity analyses, if performed. |
| Case-by-case analysis | 10 | Present the case-by-case analysis of key variables. Present the causality assessment, if applicable. |
| *Discussion* | | |
| Key results | 11 | Discuss key results with reference to study objectives and contextualize them within the current literature and other consulted sources. Clearly discriminate between expected reactions and emerging safety signals. |
| External validity | 12a | Discuss the external validity of the results to the general population. |
| | 12b | Discuss the potential relevance of results in clinical practice |
| | 12c | Propose further study designs if applicable |
| Limitations | 13 | Present general limitations, making clear that disproportionality analysis alone cannot prove causation or measure incidence, and specific limitations, including confounding and reporting bias and efforts to mitigate them. |

**Table 1** (continued)

| Section and topic | Item # | Checklist item |
|---|---|---|
| *Declarations* | | |
| | 14a | Provide the source of funding/sponsorship and the role of the funders/sponsors for the present study and for any original study on which the present article is based. |
| | 14b | Clearly identify potential commercial and intellectual conflicts of interest (e.g., link to any drug/event investigated, whether financial, legal action, or software used). |
| | 14c | Declare any institutional approval needed or granted in the investigation. |
| | 14d | Include a statement on data availability, code availability (including the version of the statistical software used), and protocol registration. |

*READUS-PV* REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance

**Table 2** The READUS-PV checklist for abstracts for standalone studies

| Section and topic | Item # | Checklist item |
|---|---|---|
| Background | 1a | State the aim/rationale for performing the study. |
| | 1b | Specify the adverse event(s) and/or the drug(s) under study, when applicable. |
| | 1c | Specify the specific population or setting, when applicable. |
| Methods | 2a | Identify the study as a "disproportionality analysis" and specify the type of data used. |
| | 2b | Specify the name of the database(s) used and the type of access. |
| | 2c | Specify the timeframe and geographical region, when applicable. |
| | 2d | Specify the disproportionality measure(s) used and their statistical significance threshold(s). |
| | 2e | Specify if a case-by-case analysis is performed. |
| Results | 3 | Report main findings including their precision (e.g., 95% confidence intervals), together with a short summary of the case-by-case analysis. |
| Conclusion | 4a | Clearly report key conclusions. |
| | 4b | Acknowledge that the disproportionality analysis is a hypothesis generating or refinement approach. |
| | 4c | State the implications and clinical relevance of the findings. |

*READUS-PV* REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance

compliance with these guidelines is suboptimal even in journals that actively endorse them [37]. Various strategies to increase the use of reporting guidelines have therefore been proposed, e.g., training, encouraging and checking adherence, providing feedback, or involving experts [38]. Moreover, endorsement by scientific societies and professional networks and inclusion in pharmacovigilance curricula should be envisioned [39]. Most of these strategies have not been evaluated by robust designs, while convincing evidence suggests a pivotal role for the involvement of journal editors [32, 38, 40]. We therefore encourage journal editors and publishers to raise awareness of READUS-PV, endorse its use (for example, by referring to it in the "Instructions for authors" section of the journal), and advise editors and peer reviewers to consider the READUS-PV checklists. Guidance for journal editors for endorsing READUS-PV guidelines is provided on the website. Moreover, we recommend authors submit the reporting template (downloadable from https:// readus-statement.org/) along with their submission, indicating where information for each item is reported.

Although these guidelines primarily focus on disproportionality analyses, SDRs alone cannot constitute safety signals and should instead be assessed through a case-by-case analysis and contextualized with evidence from other data sources and methods [13]. The checklist items are partly applicable to other signal detection studies on ICSR databases, such as other observed-to-expected analyses (i.e., where the expected number of ICSRs is defined using epidemiological data), mixed approaches with meta-analyses, or pharmacoepidemiologic studies, but should be used in concomitance with other reporting guidelines when appropriate.

## 3.1 Limitations

In developing the READUS-PV guidelines, we have set up a large panel of international experts in pharmacovigilance, disproportionality analysis, and assessment of safety

signals, including researchers from universities, the pharmaceutical industry, and regulatory agencies. Although we have tried to widely spread our invitations to participate, we may have missed out on people with expertise in the field, particularly in non-European countries, but we hope that more experts will be involved in revising or extending the guidelines. We acknowledge that periodic updates and refinements will be necessary to ensure the READUS-PV guidelines encompass the latest advancements in the field, and item inclusion may be rediscussed (see Supplementary Table 3 in the electronic supplementary material for excluded items). We encourage all users of this checklist to share comments and suggestions for improvement through the dedicated platform in the READUS-PV website. Finally, the actual impact of these guidelines deserves specific studies and will be assessed after relevant implementation and dissemination within the scientific community. Given translation of reporting guideline checklists to scoring systems has been shown to be heterogenous among meta-research studies and poorly reported, the development of a uniform adherence-scoring tool to evaluate adherence to READUS-PV guidelines will be developed [41, 42].

## 4 Conclusion

The READUS-PV statement is provided to benefit authors, editors, peer-reviewers, and users of disproportionality analyses on ICSR databases. Ultimately, we hope that the uptake of these guidelines will lead to more transparent, complete, and accurate reporting and interpretation of disproportionality analyses, thus facilitating integration of evidence from disproportionality analyses with evidence from other data sources and actual clinical transferability for evidence-based decision-making.

## Declarations

## References

1. CIOMS-Cumulative-PV-Glossary-v1.0.pdf [Internet]. [cited 2023 Jul 11]. Available from https://cioms.ch/wp-content/uploads/2021/03/CIOMS-Cumulative-PV-Glossary-v1.0.pdf. Accessed 6 Mar 2024.
2. Croteau D, Pinnow E, Wu E, Muñoz M, Bulatao I, Dal Pan G. Sources of evidence triggering and supporting safety-related labeling changes: a 10-year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug Administration. Drug Saf. 2022;45:169–80.
3. Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, Gross-Martirosyan L. Characteristics of drugs safety signals that predict

safety related product information update. Pharmacoepidemiol Drug Saf. 2018;27:789–96.

4. Tau N, Shochat T, Gafter-Gvili A, Tibau A, Amir E, Shepshelovich D. Association between data sources and US Food and Drug Administration drug safety communications. JAMA Intern Med. 2019;179:1590–2.

5. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:1–11.

6. Pham M, Cheng F, Ramachandran K. A Comparison study of algorithms to detect drug-adverse event associations: frequentist, Bayesian, and machine-learning approaches. Drug Saf. 2019;42:743–50.

7. Faillie J-L. Case–non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225–32.

8. Raschi E, Moretti U, Salvo F, Pariente A, Antonazzo IC, Ponti FD, et al. Evolving roles of spontaneous reporting systems to assess and monitor drug safety. Pharmacovigilance [Internet]. 2018 [cited 2020 Dec 1]; Available from https://www.intechopen.com/books/pharmacovigilance/evolving-roles-of-spontaneous-reporting-systems-to-assess-and-monitor-drug-safety. Accessed 6 Mar 2024.

9. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32:99–110.

10. Khouri C, Fusaroli M, Salvo F, Raschi E. Interpretation of pharmacovigilance disproportionality analyses. Clin Pharmacol Ther. 2023;114:745–6.

11. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.

12. Council for International Organizations of Medical Sciences, editor. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva: CIOMS; 2010.

13. Fusaroli M, Salvo F, Bernardeau C, Idris M, Dolladille C, Pariente A, et al. Mapping strategies to assess and increase the validity of published disproportionality signals: a meta-research study. Drug Saf. 2023;46:857–66. https://doi.org/10.1007/s40264-023-01329-w.

14. Farcaş A, Măhălean A, Bulik NB, Leucuta D, Mogoşan C. New safety signals assessed by the pharmacovigilance risk assessment committee at EU level in 2014–2017. Expert Rev Clin Pharmacol. 2018;11:1045–51.

15. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91:1010–21.

16. Dhodapkar MM, Shi X, Ramachandran R, Chen EM, Wallach JD, Ross JS. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008–19: cross sectional study. BMJ. 2022;379: e071752.

17. Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, et al. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol. 2021;139:191–8.

18. Khouri C, Fusaroli M, Salvo F, Raschi E. Transparency and robustness of safety signals. BMJ. 2022;379: o2588.

19. Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021;138:73–9.

20. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet Lond Engl. 2014;383:267–76.

21. Boutron I, Ravaud P. Misrepresentation and distortion of research in biomedical literature. Proc Natl Acad Sci. 2018;115:2613–9.

22. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet Lond Engl. 2009;374:86–9.

23. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.

24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

25. Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363: k3532.

26. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.

27. European Medicines Agency. Good pharmacovigilance practices [Internet]. Eur. Med. Agency. 2018 [cited 2021 Dec 6]. Available from https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices. Accessed 6 Mar 2024.

28. Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39:469–90.

29. Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff. Available from https://www.fda.gov/media/130216/download?attachment. Accessed 6 Mar 2024.

30. Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug Safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. https://doi.org/10.1007/s40264-024-01423-7.

31. Bégaud B, Judith KJ. Assessing causality from case reports. In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of pharmacoepidemiology. 3rd ed. New York: Wiley; 2021. p. 246–56.

32. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLOS Med. 2010;7:e1000217.

33. Nicholls SG, Langan SM, Benchimol EI, Moher D. Reporting transparency: making the ethical mandate explicit. BMC Med. 2016;14:44.

34. ICMJE | Recommendations | Browse [Internet]. [cited 2023 Jul 19]. Available from https://www.icmje.org/recommendations/browse/. Accessed 6 Mar 2024.

35. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.

36. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006;185:263–7.

37. Stevens A, Shamseer L, Weinstein E, Yazdi F, Turner L, Thielman J, et al. Relation of completeness of reporting of health research to journals' endorsement of reporting guidelines: systematic review. BMJ. 2014;348: g3804.

38. Blanco D, Altman D, Moher D, Boutron I, Kirkham JJ, Cobo E. Scoping review on interventions to improve adherence to reporting guidelines in health research. BMJ Open. 2019;9:e026589.

39. van Eekeren R, Rolfes L, Koster AS, Magro L, Parthasarathi G, Al Ramimmy H, et al. What future healthcare professionals need to know about pharmacovigilance: introduction of the WHO PV core curriculum for university teaching with focus on clinical aspects. Drug Saf. 2018;41:1003–11.

40. Pandis N, Shamseer L, Kokich VG, Fleming PS, Moher D. Active implementation strategy of CONSORT adherence by a dental specialty journal improved randomized clinical trial reporting. J Clin Epidemiol. 2014;67:1044–8.

41. Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, et al. Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019;9: e025611.

42. Dal Santo T, Rice DB, Amiri LSN, Tasleem A, Li K, Boruff JT, et al. Methods and results of studies on reporting guideline adherence are poorly reported: a meta-research study. J Clin Epidemiol. 2023;159:225–34.

## Authors and Affiliations

**Michele Fusaroli[1] · Francesco Salvo[2,3] · Bernard Begaud[2] · Thamir M. AlShammari[4] · Andrew Bate[5,6] · Vera Battini[7] · Andreas Brueckner[8] · Gianmario Candore[9] · Carla Carnovale[7] · Salvatore Crisafulli[10] · Paola Maria Cutroneo[11] · Charles Dolladille[12,13] · Milou-Daniel Drici[14] · Jean-Luc Faillie[15] · Adam Goldman[16,17] · Manfred Hauben[18,19] · Maria Teresa Herdeiro[20] · Olivia Mahaux[5] · Katrin Manlik[9] · François Montastruc[21,22] · Yoshihiro Noguchi[23] · G. Niklas Norén[24] · Roberta Noseda[25] · Igho J. Onakpoya[26] · Antoine Pariente[2,3] · Elisabetta Poluzzi[1] · Myriam Salem[27] · Daniele Sartori[24,28] · Nhung T. H. Trinh[29] · Marco Tuccori[30] · Florence van Hunsel[31,32] · Eugène van Puijenbroek[31,32] · Emanuel Raschi[1] · Charles Khouri[33,34]**

✉ Emanuel Raschi
emanuel.raschi@unibo.it

✉ Charles Khouri
ckhouri@chu-grenoble.fr

Francesco Salvo
francesco.salvo@u-bordeaux.fr

1    Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy

2    Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000 Bordeaux, France

3    Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000 Bordeaux, France

4    College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia

5    Global Safety, GSK, Brentford, UK

6    Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

7    Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy

8    Novartis, Basel, Switzerland

9    Bayer AG, Medical Affairs and Pharmacovigilance, Berlin, Germany

10    Department of Medicine, University of Verona, Verona, Italy

11    Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy

12    UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France

13    Department of Pharmacology, CHU de Caen Normandie, Caen, France

14    Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France

15    Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France

16    Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel

17    Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

18    Pfizer Inc., New York, USA

19    Department of Family and CommunityMedicine, New York Medical College, Valhalla, New York, USA

20    Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193 Aveiro, Portugal

21    Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France

22    CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France

23    Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan

24    Uppsala Monitoring Centre, Uppsala, Sweden

25    Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland

26  Department for Continuing Education, University of Oxford, Oxford, UK

27  Health Canada, Ottawa, Canada

28  Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

29  PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway

30  Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy

31  Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands

32  University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, Groningen, the Netherlands

33  Pharmacovigilance Department, Univ. Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France

34  UMR 1300-HP2 Laboratory, Univ. Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France